Company Update and EOFY 2023 Information
Melbourne, 4 Aug 2023: Australian vaccine development company BioDiem Ltd today and its subsidiary company Opal Biosciences Ltd (“Opal”) are pleased to provide the following update.
Live attenuated flu virus (LAIV) vaccine
China-based Changchun BCHT Biotechnology Co (BCHT) holds an exclusive licence from BioDiem for the vaccine technology based on the live attenuated influenza virus (LAIV). BCHT’s licence covers the private sector market in China for pandemic and seasonal influenza vaccines made using an egg-based production method. BCHT holds a complementary licence to the LAIV for the public market in China via a sublicence from the World Health Organisation. BioDiem received a payment from BCHT of US$241,852 in February 2023.
Opal Biosciences Ltd (“Opal”)
EOFY Share Price information*
The EOFY 2023 share price information is as follows being the pricing of the last capital raise:
For those BioDiem shareholders who also separately hold shares in Opal, the EOFY 2023 share price of Opal Biosciences ordinary shares is $0.075 (7.5 cents) being the pricing of the last capital raise.
*The Company does not provide any advice regarding valuation, and shareholders are encouraged to seek their own professional advice in relation to valuation of their shares.
Shareholder Information at Share Registry, Computershare.
Shareholders are asked to ensure their contact details/email addresses are up-to-date at Computershare. This can be done online via the Computershare Investor Centre (www.computershare.com.au)
